Drug intelligence / Profile preview

CMAB801

Development stage: Unknown
Lead developer: Taizhou Mabtech Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

CMAB801 is a biosimilar candidate of bevacizumab (Avastin), a recombinant humanized monoclonal IgG1 antibody that targets vascular endothelial growth factor A (VEGF-A). Developed by Taizhou Mabtech Pharmaceutical (a subsidiary of Mabpharm), CMAB801 is designed to inhibit tumor angiogenesis by preventing the binding of VEGF-A to its receptors, VEGFR-1 and VEGFR-2. The drug is being evaluated in clinical trials in China, including a Phase I pharmacokinetic similarity study comparing CMAB801 to Avastin in healthy adult male volunteers, with primary potential indications in non-small cell lung cancer (NSCLC) and metastatic colorectal cancer.

Brand names: Maituo
Other names: bevacizumab biosimilar

Targets

VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on CMAB801.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CMAB801.

Explore the full profile